Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults
A study is underway to evaluate the efficacy and safety of dupilumab in treating bullous pemphigoid, an autoimmune blistering disease.
Asset / Drug
Drug and asset intelligence for dupilumab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.